Lee Anthony J, Noon Kathleen R, Jianmongkol Suree, Lau Miranda, Jenkins Gary J, Osawa Yoichi
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan 48109-0632, USA.
Chem Res Toxicol. 2005 Dec;18(12):1927-33. doi: 10.1021/tx050263c.
It is established that aminoguanidine (AG), diaminoguanidine (DAG), and NG-amino-l-arginine (NAA) are metabolism-based inactivators of the three major isoforms of nitric oxide synthase (NOS). In the case of neuronal NOS (nNOS), heme alteration is known to be a major cause of inactivation, although the exact mechanism by which this occurs is not well-understood. We show here by the use of LC/MS/MS techniques that AG, DAG, and NAA are metabolized by nNOS to products with corresponding mass ions at m/z of 45.2, 60.2, and 160.0, respectively. These results are consistent with the loss of a hydrazine moiety from each inactivator. These findings are confirmed by exact mass measurements and comparison to authentic standards in the case of the products for NAA and AG, respectively. Moreover, the major dissociable heme product that was formed during inactivation of nNOS by AG, DAG, and NAA had molecular ions at m/z 660.2, 675.2, and 775.3, respectively. These results are consistent with an adduct of heme and inactivator minus a hydrazine moiety. In support of this, MS/MS studies reveal a fragment ion of heme in each case. With the use of 14C-labeled heme, we also show that in the case of AG, the dissociable heme adduct accounts for approximately one-half of the heme that is altered. In addition, we employ a software-based differential metabolic profiling method by subtracting LC/MS data sets derived from samples that contained nNOS from those that did not contain the enzyme to search for products and substrates in complex reaction mixtures. The metabolic profiling method established in this study can be used as a general tool to search for substrates and products of enzyme systems, including the drug-metabolizing liver microsomal P450 cytochromes. We propose that the metabolism-based inactivation of nNOS by AG, DAG, and NAA occurs through oxidative removal of the hydrazine group and the formation of a radical intermediate that forms stable products after H-atom abstraction or reacts with the heme prosthetic moiety and inactivates nNOS.
已确定氨基胍(AG)、二氨基胍(DAG)和NG-氨基-L-精氨酸(NAA)是基于代谢的一氧化氮合酶(NOS)三种主要同工型的失活剂。就神经元型一氧化氮合酶(nNOS)而言,血红素改变是失活的主要原因,尽管其确切发生机制尚不清楚。我们在此通过液相色谱/串联质谱(LC/MS/MS)技术表明,AG、DAG和NAA被nNOS代谢为分别具有质荷比(m/z)为45.2、60.2和160.0的相应质量离子的产物。这些结果与每种失活剂中肼基部分的丢失一致。在NAA和AG产物的情况下,通过精确质量测量并与真实标准品比较,证实了这些发现。此外,在AG、DAG和NAA使nNOS失活过程中形成的主要可解离血红素产物的分子离子质荷比分别为660.2、675.2和775.3。这些结果与血红素和失活剂减去一个肼基部分的加合物一致。为此提供支持的是,串联质谱研究在每种情况下都揭示了血红素的一个碎片离子。使用14C标记的血红素,我们还表明,就AG而言,可解离的血红素加合物约占改变的血红素的一半。此外,我们采用一种基于软件的差异代谢谱分析方法,从不含该酶的样品的液相色谱/质谱数据集中减去含有nNOS的样品的数据集,以在复杂反应混合物中寻找产物和底物。本研究中建立的代谢谱分析方法可作为一种通用工具,用于寻找酶系统的底物和产物,包括药物代谢性肝微粒体细胞色素P450。我们提出,AG、DAG和NAA基于代谢使nNOS失活是通过肼基的氧化去除以及形成自由基中间体来实现的,该自由基中间体在夺取氢原子后形成稳定产物或与血红素辅基部分反应并使nNOS失活。